The IRB's role in assessing the generalizability of non-NIH-funded clinical trials.
D000367:Age Factors; D004345:Drug Industry; D015507:Drugs, Investigational; D026724:Ethical Review; D004989:Ethics; D017041:Ethics Committees; D028744:Ethics Committees, Research; D035082:Federal Government; D005260:Female; D005378:Financial Support; D005380:Financing, Government; D006076:Government; D033161:Government Regulation; D017408:Guidelines as Topic; D006805:Human Experimentation; D006801:Humans; D008913:Minority Groups; D009316:National Institutes of Health (U.S.); D033281:Nontherapeutic Human Experimentation; D018579:Patient Selection; D009272:Persons; D012106:Research; D012107:Research Design; D035842:Research Subjects; D012306:Risk; D018570:Risk Assessment; D012926:Social Control, Formal; D036302:Therapeutic Human Experimentation; D014481:United States; D014486:United States Food and Drug Administration; D035862:Vulnerable Populations; D014930:Women
Biomedical and Behavioral Research; NIH Guidelines; National Institutes of Health